Processa Pharmaceuticals, Inc.'s CEO, George K. Ng, reported an open-market purchase of 1,843 shares of common stock at $2.97 per share on April 15, 2...
Neutral
Processa Pharmaceuticals announced that Dr. Sian Bigora, its Chief Development and Regulatory Officer, will transition to a part-time role effective M...
Processa Pharmaceuticals (PCSA) CEO George K. Ng reported an open-market purchase of 2,136 shares of common stock at $2.535 per share. After this tran...